Enzo Biochem PE Ratio 2010-2023 | ENZ
Current and historical p/e ratio for Enzo Biochem (ENZ) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Enzo Biochem PE ratio as of June 06, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Enzo Biochem PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-06-06 |
2.21 |
|
0.00 |
| 2023-01-31 |
1.34 |
$-0.72 |
0.00 |
| 2022-10-31 |
2.14 |
$-0.54 |
0.00 |
| 2022-07-31 |
2.37 |
$-0.37 |
0.00 |
| 2022-04-30 |
2.55 |
$-0.13 |
0.00 |
| 2022-01-31 |
3.22 |
$0.01 |
322.00 |
| 2021-10-31 |
3.44 |
$0.11 |
31.27 |
| 2021-07-31 |
3.26 |
$0.17 |
19.18 |
| 2021-04-30 |
3.07 |
$0.03 |
102.33 |
| 2021-01-31 |
2.82 |
$-0.22 |
0.00 |
| 2020-10-31 |
1.82 |
$-0.43 |
0.00 |
| 2020-07-31 |
2.38 |
$-0.60 |
0.00 |
| 2020-04-30 |
3.02 |
$-0.64 |
0.00 |
| 2020-01-31 |
2.51 |
$0.04 |
62.75 |
| 2019-10-31 |
3.16 |
$0.02 |
158.00 |
| 2019-07-31 |
3.91 |
$0.05 |
78.20 |
| 2019-04-30 |
3.47 |
$0.04 |
86.75 |
| 2019-01-31 |
3.76 |
$-0.49 |
0.00 |
| 2018-10-31 |
3.32 |
$-0.33 |
0.00 |
| 2018-07-31 |
4.42 |
$-0.21 |
0.00 |
| 2018-04-30 |
6.00 |
$-0.09 |
0.00 |
| 2018-01-31 |
7.36 |
$-0.03 |
0.00 |
| 2017-10-31 |
9.85 |
$-0.03 |
0.00 |
| 2017-07-31 |
10.85 |
$-0.05 |
0.00 |
| 2017-04-30 |
8.80 |
$0.72 |
12.22 |
| 2017-01-31 |
6.68 |
$0.67 |
9.97 |
| 2016-10-31 |
6.10 |
$0.84 |
7.26 |
| 2016-07-31 |
6.97 |
$0.97 |
7.19 |
| 2016-04-30 |
4.98 |
$0.38 |
13.11 |
| 2016-01-31 |
4.74 |
$0.37 |
12.81 |
| 2015-10-31 |
3.72 |
$0.13 |
28.62 |
| 2015-07-31 |
3.00 |
$-0.05 |
0.00 |
| 2015-04-30 |
2.80 |
$-0.30 |
0.00 |
| 2015-01-31 |
3.15 |
$-0.25 |
0.00 |
| 2014-10-31 |
5.22 |
$-0.25 |
0.00 |
| 2014-07-31 |
4.80 |
$-0.24 |
0.00 |
| 2014-04-30 |
4.20 |
$-0.25 |
0.00 |
| 2014-01-31 |
2.81 |
$-0.39 |
0.00 |
| 2013-10-31 |
2.49 |
$-0.44 |
0.00 |
| 2013-07-31 |
2.18 |
$-0.46 |
0.00 |
| 2013-04-30 |
2.24 |
$-1.07 |
0.00 |
| 2013-01-31 |
2.89 |
$-1.01 |
0.00 |
| 2012-10-31 |
2.00 |
$-0.98 |
0.00 |
| 2012-07-31 |
1.50 |
$-1.01 |
0.00 |
| 2012-04-30 |
2.74 |
$-0.43 |
0.00 |
| 2012-01-31 |
2.55 |
$-0.39 |
0.00 |
| 2011-10-31 |
2.86 |
$-0.43 |
0.00 |
| 2011-07-31 |
3.84 |
$-0.34 |
0.00 |
| 2011-04-30 |
3.99 |
$-0.38 |
0.00 |
| 2011-01-31 |
4.96 |
$-0.45 |
0.00 |
| 2010-10-31 |
4.31 |
$-0.57 |
0.00 |
| 2010-07-31 |
4.60 |
$-0.59 |
0.00 |
| 2010-04-30 |
5.97 |
$-0.58 |
0.00 |
| 2010-01-31 |
4.74 |
$-0.57 |
0.00 |
| 2009-10-31 |
5.51 |
$-0.50 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.110B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
